Klotho Neurosciences Initiates Manufacturing with AAVnerGene Technology.

Klotho Neurosciences has signed a binding agreement with AAVnerGene to initiate manufacturing and development of its KLTO-202 gene therapy candidate. AAVnerGene is a biotech company known for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery. The KLTO-202 gene therapy is designed to modify diseases using a human gene and protein derived from the patented form of the "anti-aging" Klotho gene. The agreement marks a key milestone in the development of the biotech product.

Klotho Neurosciences, Inc. (KLTO) has signed a binding agreement with AAVnerGene to initiate manufacturing and development of its KLTO-202 gene therapy candidate. The agreement marks a significant milestone in the company's efforts to develop innovative, disease-modifying cell and gene therapies using a human gene and protein derived from its patented form of the "anti-aging" Klotho gene [1].

AAVnerGene is a biotech company renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery. The KLTO-202 gene therapy is designed to modify diseases by introducing the Klotho gene into targeted cells. Dr. Joseph Sinkule, KLOTHO CEO, stated, "The AAVnerGene technology is a game-changer in manufacturing AAV vectors for intracellular delivery of genes. The initiation of manufacturing is a key milestone in the development of any biotech product" [1].

The agreement leverages AAVnerGene's cutting-edge 'AAVone' platform technology and engineered HEK293 cell line to introduce the plasmid DNA containing the Klotho gene. This approach aims to produce AAV particles with higher titer concentrations, fewer impurities, and optimized production times compared to traditional methods [1].

One of the major challenges facing AAV-vectored gene therapies is the propensity of the AAVs to home in on the liver and induce an inflammatory response. AAVnerGene has developed a series of specific tissue-targeting AAVs using its 'ATHENA' platform technology. The tissue-specific targeting of KLTO gene therapy product candidates containing tissue-specific promoters is expected to enhance safety and efficacy [1].

The agreement is a strategic move for Klotho Neurosciences to accelerate the development of its gene therapy products. By partnering with AAVnerGene, KLOTHO aims to launch its product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current 'triple transfection' manufacturing method [1].

Klotho Neurosciences, Inc. is a biotechnology company focused on developing innovative, disease-modifying cell and gene therapies. The company's portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays [2].

References:
[1] https://www.prnewswire.com/news-releases/klotho-neurosciences-inc-klotho-initiates-manufacturing-of-klto-202-product-candidate-using-aavnergenes-platform-technology-302527184.html
[2] https://www.morningstar.com/news/pr-newswire/20250812la49406/klotho-neurosciences-inc-klotho-initiates-manufacturing-of-klto-202-product-candidate-using-aavnergenes-platform-technology